Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 781 to 790 of 1627 total matches.

Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
retention (2%). ApplicationThe Medical Letter ® Vol. 66 (1709) August 19, 2024 134 site reactions ...
The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium (Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years old.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):133-4   doi:10.58347/tml.2024.1709c |  Show IntroductionHide Introduction

Aceclidine (Vizz) for Presbyopia

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2025  (Issue 1741)
on day 1, 3 hours after treatment. The Medical Letter ® Vol. 67 (1741) November 10, 2025 178 Table 1 ...
The FDA has approved Vizz (Lenz Therapeutics), a 1.44% ophthalmic solution of the cholinergic agonist aceclidine, for treatment of presbyopia in adults. Aceclidine has been available in the EU for years for treatment of open-angle glaucoma.
Med Lett Drugs Ther. 2025 Nov 10;67(1741):177-8   doi:10.58347/tml.2025.1741a |  Show IntroductionHide Introduction

Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2025  (Issue 1741)
0.22 vs 2.07 attacks per month; relative reduction 89% [95% CI 76%-95%]).7 The Medical Letter ® Vol ...
The FDA has approved garadacimab-gxii (Andembry – CSL Behring), a subcutaneously injected inhibitor of activated clotting factor XII, for prevention of hereditary angioedema (HAE) attacks in patients ≥12 years old. Garadacimab is the first activated factor XII inhibitor to become available in the US for HAE prophylaxis
Med Lett Drugs Ther. 2025 Nov 10;67(1741):181-2   doi:10.58347/tml.2025.1741c |  Show IntroductionHide Introduction

Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2026  (Issue 1752)
. The Medical Letter ® Vol. 68 (1752) April 13, 2026 60 1. M Rehorn et al. Prevalence and incidence ...
The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Cardamyst is the first product containing etripamil to be approved in the US. It is being marketed as the only FDA-approved, self-administered, rapid-acting treatment option for acute episodes of PSVT.
Med Lett Drugs Ther. 2026 Apr 13;68(1752):59-61   doi:10.58347/tml.2026.1752b |  Show IntroductionHide Introduction

Breztri Aerosphere for Asthma

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2026  (Issue 1758)
. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy. 109 The Medical Letter ® Vol. 68 (1758 ...
Breztri Aerosphere (AstraZeneca), a three-drug inhaler containing the inhaled corticosteroid (ICS) budesonide, the long-acting antimuscarinic agent (LAMA) glycopyrrolate, and the long-acting beta2-agonist (LABA) formoterol fumarate, has been approved by the FDA for maintenance treatment of asthma in patients ≥12 years old. It was approved in 2020 for treatment of chronic obstructive pulmonary disease (COPD). Breztri Aerosphere is the second ICS/LAMA/LABA combination to become available for treatment of asthma. Trelegy Ellipta, which contains the ICS fluticasone, the...
Med Lett Drugs Ther. 2026 Jul 6;68(1758):108-9   doi:10.58347/tml.2026.1758c |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
from The Medical Letter • Vol. 7 (Issue 84) August 2009 with 50-100 mcg/day, but others begin with full ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Drugs for HIV Infection

   
Treatment Guidelines from The Medical Letter • Feb 01, 2014  (Issue 138)
for HIV Infection 8 Treatment Guidelines from The Medical Letter • Vol. 12 (Issue 138) • February 2014 ...
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are available.
Treat Guidel Med Lett. 2014 Feb;12(138):7-16 |  Show IntroductionHide Introduction

Antibacterial Drugs for Community-Acquired Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
heart, lung, liver or renal disease, diabetes, alcoholism, malignancy, or 11 The Medical Letter ® Vol ...
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):10-5 |  Show IntroductionHide Introduction

Drugs for Hypothyroidism

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
) ................... p 27 The Medical Letter ® Vol. 65 (1670) February 20, 2023 Thyroid Function Tests (TFTs ...
Primary hypothyroidism is usually the result of Hashimoto's (autoimmune) thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine (LT4; synthetic thyroxine; Synthroid, and others) is the drug of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9   doi:10.58347/tml.2023.1670a |  Show IntroductionHide Introduction

Acetaminophen Safety

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2002  (Issue 1142)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 44 (W1142A ...
An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen (www.fda.gov, search "acetaminophen hepatotoxicity").
Med Lett Drugs Ther. 2002 Oct 28;44(1142):91-3 |  Show IntroductionHide Introduction